SCENAR Therapy in Chronic Non-specific Neck Pain
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorHopital Foch
About this trial
Shifting away from a medication-centered approach is a major public health priority, particularly in chronic pain management, where non-pharmacological therapies are recommended despite barriers such as limited evidence and low prescriber awareness.
SCENAR (Self-Controlled Energo-Neuro Adaptive Regulation), an electrotherapy device, lacks robust randomized controlled trial data. A prior study showed effects in both active and placebo groups after a single session, supporting further investigation.
This study aims to assess whether repeated SCENAR sessions improve disability, mobility, and pain in patients with chronic neck pain.
Eligibility criteria
Qualifiers
Male or female participants aged 18 years or older
Patients with chronic non-specific cervical spine pain, including cervicobrachial neuralgia, persisting for at least 3 months, with no identifiable underlying cause requiring specific treatment.
Patients who attended a pain clinic consultation or were referred to a pain specialist during hospitalization.
Neck Disability Index (NDI) score of at least 30% (≥15 points).
Disqualifiers
Pregnant women
Skin conditions preventing SCENAR use (wounds, recent scars, skin infections)
Initiation or change of analgesic treatment within 15 days prior to inclusion or during the study
Cervical pain related to inflammatory (spondyloarthropathy, rheumatoid arthritis, chondrocalcinosis), traumatic (fractures, dislocations), tumor-related (metastases, myeloma), infectious (spondylodiscitis), or neurological (intramedullary or posterior fossa tumor) causes
Trial design
Treatments tested in this trial
- Active SCENAR device therapy
- Sham SCENAR device Therapy
Treatment groups
76 Participants
are divided into 2 treatment groupsSponsors and collaborators
Hopital Foch
Lead sponsor
Fondation Apicil
Collaborator
Source ClinicalTrials.gov